Intercept Pharmaceuticals, Inc. (ICPT)

$18.57

+1.17 (+6.72%)
Rating:
Recommendation:
Buy
Symbol ICPT
Price $18.57
Beta 1.271
Volume Avg. 1.03M
Market Cap 551.772M
Shares () -
52 Week Range 11.6-22.36
1y Target Est -
DCF Unlevered ICPT DCF ->
DCF Levered ICPT LDCF ->
ROE 29.86% Buy
ROA -13.57% Sell
Operating Margin -
Debt / Equity -235.40% Sell
P/E -
P/B -1.48 Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ICPT news


Dr. Mark Pruzanski
Healthcare
Biotechnology
NASDAQ Global Select

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.